E-LIB Suche - Ergebnisse für: Yamamoto, Noboru

1

Immunogenicity after vaccination of COVID-19 vaccines in pa..:

Katsuya, Yuki ; Yoshida, Tatsuya ; Takashima, Atsuo...
International Journal of Clinical Oncology. 29 (2024) 4 - p. 386-397 , 2024

Link: https://doi.org/10.1007/..

2

Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin ..:

Yamamoto, Noboru ; Tolcher, Anthony ; Hafez, Navid...
OncoTargets and Therapy. 17 (2024) - p. 267-280 , 2024

Link: https://doi.org/10.2147/..

3

Phase I study of the anti-TIGIT antibody tiragolumab in com..:

Yamamoto, Noboru ; Koyama, Takafumi ; Sato, Jun...
Cancer Chemotherapy and Pharmacology. , 2024

Link: https://doi.org/10.1007/..

4

A phase 1/1b, open-label, dose-escalation study of PD-1 inh..:

Yamamoto, Noboru ; Kuboki, Yasutoshi ; Harano, Kenichi...
Investigational New Drugs. , 2024

Link: https://doi.org/10.1007/..

5

Dabrafenib and trametinib administration in patients with B..:

Shimoi, Tatsunori ; Sunami, Kuniko ; Tahara, Makoto...
eClinicalMedicine. 69 (2024) - p. 102447 , 2024

Link: https://doi.org/10.1016/..

6

Clinical management, monitoring, and prophylaxis of adverse..:

Heist, Rebecca S. ; Sands, Jacob ; Bardia, Aditya...
Cancer Treatment Reviews. 125 (2024) - p. 102720 , 2024

Link: https://doi.org/10.1016/..

7

First-in-human study of naporafenib (LXH254) with or withou..:

Janku, Filip ; Kim, Tae Min ; Iyer, Gopakumar...
European Journal of Cancer. 196 (2024) - p. 113458 , 2024

Link: https://doi.org/10.1016/..

8

PD‐1 inhibition with retifanlimab and/or arginase inhibitio..:

Kuboki, Yasutoshi ; Koyama, Takafumi ; Matsubara, Nobuaki...
Cancer Medicine. 13 (2024) 8 - p. , 2024

Link: https://doi.org/10.1002/..

9

Safety, tolerability, pharmacokinetics, and antitumor activ..:

Kondo, Shunsuke ; Katsuya, Yuki ; Yonemori, Kan...
Cancer Treatment and Research Communications. 39 (2024) - p. 100809 , 2024

Link: https://doi.org/10.1016/..

10

Distinct Progression and Efficacy of First-Line Osimertinib..:

Takeyasu, Yuki ; Yoshida, Tatsuya ; Masuda, Ken...
JTO Clinical and Research Reports. 5 (2024) 2 - p. 100636 , 2024

Link: https://doi.org/10.1016/..

11

A molecular glue RBM39-degrader induces synthetic lethality..:

Kohsaka, Shinji ; Yagishita, Shigehiro ; Shirai, Yukina...
npj Precision Oncology. 8 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

12

Efficacy and safety of chemoimmunotherapy in advanced non-s..:

Tamura, Kentaro ; Okuma, Yusuke ; Nomura, Shogo...
Journal of Cancer Research and Clinical Oncology. 150 (2024) 4 - p. , 2024

Link: https://doi.org/10.1007/..

13

Correction to: Phase I study of the anti‑TIGIT antibody tir..:

Yamamoto, Noboru ; Koyama, Takafumi ; Sato, Jun...
Cancer Chemotherapy and Pharmacology. , 2024

Link: https://doi.org/10.1007/..

14

Clinical significance of inter-assay discrepancy in PD-L1 e..:

Miyakoshi, Jun ; Yoshida, Tatsuya ; Kashima, Jumpei...
Lung Cancer. 191 (2024) - p. 107788 , 2024

Link: https://doi.org/10.1016/..

15

EGFR-Mutated Lung Adenocarcinoma with Li-Fraumeni Syndrome:..:

Fujii, Hiroyuki ; Okuma, Yusuke ; Shinno, Yuki...
JTO Clinical and Research Reports. , 2024

Link: https://doi.org/10.1016/..